New Delhi: Alcon has unveiled its much-anticipated UNITY Vitreoretinal Cataract System (VCS) and UNITY Cataract System (CS) in India, marking what company leaders describe as not just another product ...

I reiterate a 'Strong Buy' rating for Alcon with a one-year price target of $115 per share, driven by new product pipelines and FDA clearances. Alcon's Unity VCS/CS systems received FDA clearance, set ...

Combined vitreoretinal-cataract system (VCS) is cleared for use in Canada New, proprietary technology is designed to deliver significant surgical and workflow efficiencies First innovation to be ...

Alcon Inc. ALC recently received the FDA’s 510(k) clearance for its Unity Vitreoretinal Cataract System (VCS) and Unity Cataract System (CS). Both the systems will be introduced from Alcon’s Unity ...

“Alcon has a long legacy of advancing phaco and vitreoretinal technology for surgical ophthalmology. With UNITY VCS/CS, we are introducing more than a dozen innovations designed to transform surgical ...

GENEVA--(BUSINESS WIRE)--Regulatory News: Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced that UNITY ® Vitreoretinal Cataract System ...

TORONTO--(BUSINESS WIRE)--Alcon, the global leader in eye care dedicated to helping people see brilliantly, today announced that UNITY ® Vitreoretinal Cataract System (VCS) has received Health Canada ...

“Today marks an important day for Canadian ophthalmologists as we introduce the next generation of equipment solutions in cataract and vitreoretinal surgery, and we are grateful to those who helped us ...

Combined vitreoretinal-cataract system (VCS) and standalone cataract system (CS) are cleared for use in the U.S. New, proprietary technologies designed to deliver transformative surgical innovation ...

CEO David Endicott pointed to building momentum in the second half of 2025, with particular strength in equipment and ocular health. Endicott highlighted, "the launch [of Unity VCS] is delivering on ...

Investing.com -- BofA Securities cut Alcon to “underperform” from “buy” rating, and lowered its price objective to CHF60 from CHF80, warning that weakened earnings prospects, slower surgical-equipment ...